Document is current
Any future updates will be listed below
-
Authors
Chen, Jianzhou https://orcid.org/0000-0002-3645-3904
Deutsch, Eric https://orcid.org/0000-0002-8223-3697
Kroemer, Guido https://orcid.org/0000-0002-9334-4405
Galluzzi, Lorenzo
Zitvogel, Laurence https://orcid.org/0000-0003-1596-0998
- License Information
-
More Information
Article History
Accepted: 13 June 2025
First Online: 14 July 2025
Competing interests
: E.D. has acted as a consultant and/or adviser of Boehringer-Ingelheim and Merck Serono, has received research funding from AstraZeneca, Boehringer-Ingelheim, Bristol Myers Squibb, IMCORE/Roche Genentech, Merck Serono and MSD, and is a founder of Graegis Pharmaceuticals. G.K. is an adviser of Hevolution and Institut Servier, is a scientific co-founder of EverImmune, Osasuna Therapeutics, Samsara Therapeutics and Therafast Bio, is on the Board of Directors of the Bristol Myers Squibb Foundation France, is the inventor of patents covering therapeutic targeting of ageing, cancer, cystic fibrosis and metabolic disorders, and has received research funding from Daiichi Sankyo, Eleor, Kaleido, Lytix Pharma, PharmaMar, Osasuna Therapeutics, Samsara Therapeutics, Sanofi, Sutro, Tollys, and Vascage; his brother (Romano Kroemer) was an employee of Sanofi and now consults for Boehringer-Ingelheim. L.G. has acted as a consultant for and/or adviser of AstraZeneca, AbbVie, Boehringer-Ingelheim, EduCom, Inzen, Imvax, the Longevity Labs, the Luke Heller TECPR2 Foundation, Noxopharm, OmniSEQ, Onxeo, Promontory and Sotio, receives research funding from Lytix Biopharma, Promontory and Onxeo, and holds stock options in Promontory. L.Z. is a founder and president of the advisory board of everImmune and receives research funding from 9 meters, Daichi Sankyo, Kaleido and Pileje. J.C. declares no competing interests.
